A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

To join this study, you would need to be an adult (18 or older) with a confirmed diagnosis of advanced cancer that has spread or returned. Importantly, your cancer must have a specific gene change called a RAS mutation. Your cancer also needs to be measurable, meaning doctors can track its size.

You should generally be well enough to take part in a study like this, meaning you can mostly go about your daily activities. You'd also need certain blood test results to show your organs are working properly. Some conditions might prevent you from joining. For example, if you're taking part in another drug trial, have severe allergies to the study drug's ingredients, or have serious gut problems that might stop the drug from being absorbed properly.

Also, if you've had major surgery recently, or if your cancer has spread to your brain in an uncontrolled way, you might not be able to participate. You shouldn't have active, recurring fluid build-up around your lungs or heart, or severe liver disease. Your doctor will review all your medical information carefully to see if this study is suitable for you.

If you decide to take part in this study, you would receive the new drug, RO7673396, as part of your treatment. The study has two main parts. In the first part, different groups of people will receive increasing doses of the drug to help doctors find the safest and most effective amount. In the second part, more people will receive that chosen dose to see if the drug helps fight their cancer.

Throughout the study, you'll have regular hospital visits. These visits will involve physical examinations, blood tests, and scans (like CT scans) to check how you're responding to the treatment and to monitor for any side effects. You'll also be asked questions about how you're feeling and any symptoms you might have. The total length of your participation will depend on how you respond to the treatment and what the doctors decide is best for your care, but you would have regular follow-up for a period after stopping the drug.